Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 59.89% is in line with its 5-year average of 65.32%, near the low end of its 5-year range (56.42%–70.48%).
1.88% below its 12-month average of 61.04%.
Reported quarterly gross margin; no daily interpolation. Q3 FY2026 (2026-06-30): 56.42%.
GROSS MARGIN
59.89%
GROSS MARGIN AVG TTM
61.04%
GROSS MARGIN AVG 3Y
63.23%
GROSS MARGIN AVG 5Y
65.32%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.88%
CURRENT VS 3Y AVG
-5.28%
CURRENT VS 5Y AVG
-8.31%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.90%
median of 561 covered companies
CURRENT VS SECTOR MEDIAN
+39.60%
vs the sector median at left
Market Cap
$357.37M
Gross Margin
98.15%
TTM Avg
96.49%
3Y Avg
98.25%
5Y Avg
98.83%
Market Cap
$357.44M
Gross Margin
93.73%
TTM Avg
92.44%
3Y Avg
93.34%
5Y Avg
78.89%
Market Cap
$359.05M
Gross Margin
99.87%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
83.33%
Market Cap
$340.28M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
75.00%
5Y Avg
66.67%
Market Cap
$337.38M
Gross Margin
62.61%
TTM Avg
61.15%
3Y Avg
61.24%
5Y Avg
64.05%
Market Cap
$375.13M
Gross Margin
25.47%
TTM Avg
27.02%
3Y Avg
15.55%
5Y Avg
5.84%
Market Cap
$378.75M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
40.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Embecta Corp. (EMBC) | $354.48M | 59.89% | 61.04% | 63.23% | 65.32% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $357.37M | 98.15% | 96.49% | 98.25% | 98.83% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $357.44M | 93.73% | 92.44% | 93.34% | 78.89% |
| Opus Genetics, Inc. (IRD)vs › | $359.05M | 99.87% | 100.00% | 100.00% | 83.33% |
| Agenus Inc. (AGEN)vs › | $342.72M | 29.63% | -10.58% | -43.61% | -33.41% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $340.28M | 0.00% | 50.00% | 75.00% | 66.67% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $337.38M | 62.61% | 61.15% | 61.24% | 64.05% |
| Canopy Growth Corporation (CGC)vs › | $375.13M | 25.47% | 27.02% | 15.55% | 5.84% |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $378.75M | 0.00% | 0.00% | 25.00% | 40.00% |
| Cabaletta Bio, Inc. (CABA)vs › | $326.11M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
59.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 56.42% |
| 2026-03-31 | 56.45% |
| 2025-12-31 | 67.23% |
| 2025-09-30 | 59.09% |
| 2025-06-30 | 65.99% |
| 2025-03-31 | 62.36% |
| 2024-12-31 | 63.73% |
| 2024-09-30 | 59.87% |
| 2024-06-30 | 68.95% |
| 2024-03-31 | 64.14% |
| 2023-12-31 | 67.04% |
| 2023-09-30 | 64.49% |
| 2023-06-30 | 66.24% |
| 2023-03-31 | 68.50% |
| 2022-12-31 | 68.48% |
| 2022-09-30 | 64.42% |
| 2022-06-30 | 69.70% |
| 2022-03-31 | 69.65% |
| 2021-12-31 | 70.48% |
| 2021-09-30 | 69.82% |
| 2021-06-30 | 68.68% |
| 2021-03-31 | 69.07% |
| 2020-12-31 | 67.05% |
